Table 2 PBR28 PET statistical analysis

From: In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration

PBR28 PET statistical test

Effect evaluated

Baseline

1 week after 6-OHDA

12 weeks after 6-OHDA

ANOVA (n = 10)

Region

F(7,56) = 7.17, p < 0.001, ηp2 = 0.47

F(7,56) = 5.34, p < 0.002, ηp2 = 0.40

F(7,56) = 2.85, p < 0.017, ηp2 = 0.26

Level

F(5,40) = 10.93, p < 0.001, ηp2 = 0.58

F(5,40) = 27.27, p < 0.001, ηp2 = 0.77

F(5,40) = 19.39, p < 0.001, ηp2 = 0.71

Region × Level

F(35,280) = 4.94, p < 0.001, ηp2 = 0.38

F(35,280) = 2.36, p < 0.032, ηp2 = 0.23

F(35,280) = 5.57, p < 0.001, ηp2 = 0.41

Treatment × Level

NR

F(5, 40) = 6.44, p < 0.002, ηp2 = 0.45

NR

Treatment × Region × Level

F(35,280) = 2.21, p < 0.015, ηp2 = 0.22

NR

NR

Combined groups polynomial trend analysis (n = 10)

Region

Quadratic: 81.1%, F(1,8) = 14.14, p < 0.006, ηp2 = 0.64

Quadratic: 89.0%, F(1,8) = 13.04, p < 0.007, ηp2 = 0.62

Quadratic: 62.4%, F(1,8) = 6.77, p < 0.032, ηp2 = 0.46

Cubic: 20.1%, F(1,8) = 4.27, p > 0.073, ηp2 = 0.35

Level

Quadratic: 60.6%, F(1,8) = 20.05, p < 0.002, ηp2 = 0.72

Linear: 71.5%, F(1,8) = 32.83, p < 0.001, ηp2 = 0.80

Linear: 60.4%, F(1,8) = 19.87, p < 0.002, ηp2 = 0.71

Linear: 38.7%, F(1,8) = 6.98, p < 0.030, ηp2 = 0.47

Quadratic: 28.5%, F(1,8) = 22.35, p < 0.001, ηp2 = 0.74

Quadratic: 39.4%, F(1,8) = 23.75, p < 0.001, ηp2 = 0.75

Treatment × Region

Cubic: 60.6%, F(1,8) = 3.03, p > 0.12, ηp2 = 0.28

Quadratic: 87.1%, F(1,8) = 1.626, p > 0.24, ηp2 = 0.17

NR

Linear: 18.4%, F(1,8) = 0.50, p > 0.5, ηp2 = 0.06

Treatment × Level

Quadratic: 84.3%, F(1,8) = 1.36, p > 0.28, ηp2 = 0.15

Linear: 92.5%, F(1,8) = 10.04, p < 0.013, ηp2 = 0.56

NR

Treatment × Region × Level

Quadratic × Linear: 42.0%, F(1,8) = 4.78, p > 0.06, ηp2 = 0.37

Linear × Linear: 21.7%, F(1,8) = 1.23, p > 0.299, ηp2 = 0.13

NR

Linear × Linear: 24.2%, F(1,8) = 7.37, p < 0.26, ηp2 = 0.48

Simple interaction test placebo (n = 5)

Region

Quadratic: 75.3%, F(1,4) = 3.27, p > 0.145, ηp2 = 0.45

Quadratic: 91.7%, F(1,4) = 7.05, p < 0.057, ηp2 = 0.64

NR

Level

Linear: 59.2%, F(1,4) = 4.6, p > 0.099, ηp2 = 0.53

Linear: 79.5%, F(1,4) = 33.10, p < 0.005, ηp2 = 0.89

NR

Quadratic: 39.4%, F(1,4) = 4.99, p > 0.089, ηp2 = 0.56

Quadratic: 20.5%, F(1,4) = 12.21, p < 0.025, ηp2 = 0.75

Region × Level

Linear × Linear: 42.3%, F(1,4) = 65.10, p < 0.001, ηp2 = 0.94

Cubic × Linear: 18.2%, F(1,4) = 0.95, p > 0.386, ηp2 = 0.19

NR

Cubic × Linear: 28.5%, F(1,4) = 5.27, p > 0.083, ηp2 = 0.57

Simple interaction test pioglitazone (n = 5)

Region

Quadratic: 74.7%, F(1,4) = 59.33, p < 0.002, ηp2 = 0.94

Quadratic: 76.7%, F(1,4) = 8.859, p < 0.040, ηp2 = 0.69

NR

Level

Quadratic: 76.6%, F(1,4) = 17.65,p < 0.014, ηp2 = 0.82

Quadratic: 52.9%, F(1,4) = 11.01, p < 0.029, ηp2 = 0.73

NR

Linear: 23.1%, F(1,4) = 2.56, p > 0.185, ηp2 = 0.39

Linear: 47.0%, F(1,4) = 4.08, p > 0.113, ηp2 = 0.51

Region × Level

Quadratic × Linear: 63.5%, F(1,4) = 8.72, p < 0.042, ηp2 = 0.69

linear × Linear: 33.1%, F(1,4) = 7.12, p > 0.056, ηp2 = 0.64

NR

  1. Results of repeated measures ANOVA and polynomial trend analysis at baseline, 1, and 12 weeks after 6-OHDA. ANOVA and combined group polynomial trend analyses were performed with animals from both treatment groups. Polynomial trend analysis for effects of treatment and simple interaction tests for individual treatment groups are reported if a treatment effect was detected by ANOVA. Repeated measures ANOVA results are included if p < 0.05. Polynomial trend results are included if contributing ≥15% to the variance of the shape of the surface plot.
  2. PET positron emission tomography, NR not reported, PBR28 N-(2-[11 C]methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide, 6-OHDA 6-hydroxydopamine, ηp2 effect size (partial eta squared)
Back to article page